Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 228

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 228
---
 (or permitted assignees under Rule 5110(e)(1)(A)) will not sell, transfer, assign, pledge, or hypothecate these warrants
or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that
would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from commencement
of sales in this offering. In addition, the Representative’s Warrants provide for registration rights upon request, in certain cases.
The one-time demand registration right provided will not be greater than five years from the commencement of sales of this offering in
compliance with FINRA Rule 5110(g)(8)(C). The piggyback registration right provided will not be greater than seven years from the commencement
of sales of this offering in compliance with FINRA Rule 5110(g)(8)(D). We will bear all fees and expenses attendant to registering the
securities issuable on exercise of the Representative’s Warrants other than underwriting commissions incurred and payable by the
holders. The exercise price and number of shares issuable upon exercise of the Representative’s Warrants may be adjusted in certain
circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger, or consolidation. However, neither
the Representative Warrant exercise price, nor the number of Ordinary Shares underlying such warrants, will be adjusted for issuances
of Ordinary Shares by us at a price below the exercise price of the Representative’s Warrants.

Discretionary Accounts

The underwriters do not intend
to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.

Lock-Up Agreements

Pursuant to certain “lock-up”
agreements, we, our executive officers and directors and current holders of our securities, have agreed, for a period of twelve (12)
months from the closing of this offering, with respect to our directors and executive officers and for a period of six (6) months from
the closing of this offering with respect to the Company and all other holders of our securities, not to (a) offer, pledge, sell, contract
to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase,
lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our capital stock or any securities convertible into
or exercisable or exchangeable for